Skip to main content

Table 4 Standardized incidence ratio (SIR) of specific cancer types among subjects in the biologics cohort and nonbiologic DMARDs cohort

From: The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study

Cancer origin Biologics SIR (95% CI) nbDMARDs SIR (95% CI)
  N Expected   N Expected  
Non-hematologic cancers 73 88.46 0.83 (0.65, 1.04) 455 347.47 1.31 (1.19, 1.44)
Oral cavity 2 4.55 0.44 (0.05, 1.59) 20 17.92 1.12 (0.68, 1.72)
Digestive system1 20 32.03 0.62 (0.38, 0.97) 135 125.75 1.07 (0.90, 1.27)
Lungs2 11 10.39 1.06 (0.53, 1.89) 57 40.77 1.40 (1.06, 1.81)
Breast, cervix3 22 19.96 1.10 (0.69, 1.67) 115 78.45 1.47 (1.21, 1.76)
Bladder/kidney4 14 15.75 0.89 (0.49, 1.49) 96 61.81 1.55 (1.26, 1.90)
Melanoma 0 0.21 - 0 0.83 -
NMSC 5 2.43 2.05 (0.66, 4.79) 15 9.58 1.57 (0.88, 2.58)
Unspecified origin 4 5.79 0.69 (0.19, 1.77) 32 22.76 1.41 (0.96, 1.99)
Hematologic cancers 5 16 3.45 4.64 (2.65, 7.53) 31 13.57 2.28 (1.55, 3.24)
Lymphoma 13 2.12 6.13 (3.26, 10.49) 21 8.34 2.52 (1.56, 3.85)
NHL 12 2.05 5.86 (3.02, 10.24) 20 8.06 2.48 (1.52, 3.83)
HL 1 0.07 13.97 (0.18, 77.7) 1 0.28 3.56 (0.05, 19.79)
Leukemia 1 1.33 0.75 (0.01, 4.18) 9 5.23 1.72 (0.79, 3.27)
  1. 1Cancers of digestive system include cancers of the stomach, colon, liver, pancreas. 2Including cancers of the lungs, bronchus and pleura. 3Including cancers of the uterus and other female reproductive organs. 4Including cancers of the prostate, testis and other male reproductive organs. 5Myeloma not included. NbDARDS, nonbiologic disease-modifying anti-rheumatic drugs; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma; NMSC, non-melanoma skin cancers; N, number.